Work

The mTOR signaling pathway as a treatment target for intracranial neoplasms

Year: 2014

Type: article

Abstract: Inhibition of the mammalian target of rapamycin (mTOR) signaling pathway has become an attractive target for human cancer therapy. Hyperactivation of mTOR has been reported in both sporadic and syndromic (hereditary) brain tumors. In contrast to the large number of successful clinical trials employing mTOR inhibitors in different types of epithelial neoplasms, their use to treat intracranial neoplasms is more limited. In this review, we summarize the role of mTOR activation in brain tumor pathogenesis and growth relevant to new human brain tumor trials currently under way using mTOR inhibitors.

Source: Neuro-Oncology

DOI: 10.1093/neuonc/nou164

Authors: D. Pachow, W. Wick, D. H. Gutmann, C. Mawrin

Institutions: German Cancer Research Center, Washington University in St. Louis, Heidelberg University, National Center for Tumor Diseases, Otto-von-Guericke-Universität Magdeburg

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Deutsche Krebshilfe